Retatrutide for Heart Failure

What Is Retatrutide and Why Is It Being Discussed for Heart Failure?

Retatrutide is a single-molecule peptide that activates three incretin and metabolic receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Eli Lilly developed the compound primarily for obesity and type 2 diabetes. It has not received FDA approval for any condition 1.

The connection to heart failure is indirect but logical. Obesity is a primary driver of HFpEF, a condition affecting roughly half of all heart failure patients. GLP-1 receptor agonists like semaglutide have demonstrated meaningful improvements in heart failure symptoms and physical limitations in patients with HFpEF and obesity 2. Because retatrutide produces greater weight loss than any single-receptor GLP-1 agonist tested to date, clinicians and researchers have raised the question of whether its effects on cardiac remodeling and hemodynamics could exceed those of existing agents. That question remains unanswered by clinical data.

The 2023 American Heart Association / American College of Cardiology heart failure guidelines already recognize obesity management as a treatment target in HFpEF 3. Semaglutide received a Class 2a recommendation for HFpEF with obesity. Retatrutide has no such recommendation.

The Phase 2 Weight-Loss Data That Sparked Interest

In the phase 2 dose-ranging trial published in the New England Journal of Medicine (N=338), retatrutide at 12 mg produced a mean body weight reduction of 24.2% at 48 weeks, compared with 2.1% in the placebo group 4. That magnitude of weight loss exceeded results seen with tirzepatide (22.5% at 72 weeks in SURMOUNT-1) and semaglutide 2.4 mg (14.9% at 68 weeks in STEP-1) 5, 6.

Weight loss of this scale carries direct hemodynamic consequences. Fat mass reduction lowers cardiac preload, reduces systemic inflammation, decreases pericardial adipose tissue volume, and improves left ventricular diastolic function. These are the same mechanisms by which semaglutide improved outcomes in STEP-HFpEF.

Dr. Milton Packer, a cardiologist at Baylor University Medical Center who has published extensively on obesity-related heart failure, has stated: "The magnitude of weight loss achieved with triple-agonist therapy could, in theory, produce cardiac benefits that surpass what we have seen with GLP-1 receptor agonists alone, but theory is not evidence" 7.

The phase 2 trial was not designed or powered to assess cardiovascular endpoints. Cardiac safety signals were limited to heart rate increases of 2 to 4 beats per minute at higher doses. No major adverse cardiovascular events (MACE) were adjudicated.

Why the Glucagon Receptor Adds Both Promise and Risk

Single-receptor GLP-1 agonists and the dual GIP/GLP-1 agonist tirzepatide have established cardiovascular safety profiles. Retatrutide's third target, the glucagon receptor, introduces pharmacology that has not been tested in a heart failure population.

Glucagon receptor activation increases hepatic glucose output, promotes lipolysis, raises energy expenditure, and may contribute to the superior weight loss seen with retatrutide. Those metabolic effects could benefit patients with obesity-related HFpEF by reducing ectopic fat deposition in and around the heart 8.

The risks are real, though. Glucagon is a positive chronotrope. It increases heart rate and myocardial contractility. In acute settings, intravenous glucagon has been used as a cardiac stimulant. For a patient with heart failure, where myocardial oxygen demand is already a concern, chronic glucagon-receptor stimulation raises questions that the current dataset cannot answer.

A 2021 review in Cardiovascular Diabetology noted that "glucagon-receptor agonism may increase cardiac workload through chronotropic and inotropic effects, and the net cardiovascular impact of dual or triple agonists incorporating glucagon activity requires dedicated outcomes trials" 8. No such trial has been completed for retatrutide.

Off-Label Status: What Prescribers Need to Understand

Retatrutide has no FDA-approved indication. It is not approved for obesity, type 2 diabetes, or any other condition. Prescribing it for heart failure is therefore not simply off-label in the traditional sense (using an approved drug for a non-approved indication). It represents use of an unapproved investigational agent outside of a clinical trial.

The FDA permits physicians to prescribe compounded or investigational medications under certain conditions, but the regulatory and liability exposure differs from standard off-label prescribing of an FDA-approved product 9.

For context, semaglutide (Wegovy) is FDA-approved for chronic weight management and has demonstrated cardiovascular risk reduction in the SELECT trial (N=17,604), where it reduced MACE by 20% compared with placebo over a median 39.8-month follow-up 10. Tirzepatide (Zepbound) is FDA-approved for obesity and showed positive results in the SURMOUNT-OSA trial for obstructive sleep apnea related to obesity 11. Retatrutide has none of these regulatory milestones behind it.

The GRADE evidence level for retatrutide in heart failure is effectively absent. There are no randomized controlled trials, no cohort studies, and no case series addressing this specific use. Clinicians considering retatrutide for a heart failure patient are operating without a safety net of population-level data.

Monitoring Requirements If Retatrutide Is Used Off-Label for Heart Failure

Given the absence of heart-failure-specific data, any off-label use of retatrutide in a patient with heart failure demands intensive monitoring. The following framework is adapted from established monitoring protocols for GLP-1 receptor agonists in cardiac patients, the 2022 AHA/ACC/HFSA heart failure guidelines 3, and pharmacovigilance principles for investigational agents.

Cardiac Biomarkers

NT-proBNP or BNP should be measured at baseline and every 4 to 6 weeks during dose titration. Rising natriuretic peptide levels may indicate worsening congestion or myocardial stress. Troponin I or T at baseline provides a reference for detecting subclinical myocardial injury. Repeat testing is warranted if a patient develops new chest discomfort or dyspnea.

Heart Rate and Rhythm

Resting heart rate should be recorded at each visit. GLP-1 agonists typically raise heart rate by 1 to 3 beats per minute. Retatrutide's glucagon component may amplify this effect. Sustained resting heart rate above 100 bpm in a heart failure patient warrants dose reduction or discontinuation. An electrocardiogram at baseline and at maximum dose is reasonable to assess QTc interval and detect new arrhythmias 12.

Volume Status and Weight

Rapid weight loss from caloric reduction can mask fluid retention in heart failure. Daily weights at home remain essential. Clinicians should distinguish between fat-mass loss (expected, gradual) and fluid shifts (rapid, potentially dangerous). Diuretic doses may require adjustment as body composition changes.

Renal Function and Electrolytes

Serum creatinine, eGFR, and electrolytes (sodium, potassium, magnesium) should be checked at baseline, 2 weeks after each dose escalation, and monthly during stable dosing. GLP-1 agonists can affect renal hemodynamics. The glucagon component increases renal blood flow acutely but long-term effects in heart failure patients are unknown 13.

Hepatic Function

Retatrutide's phase 2 data showed reductions in liver fat content, with MRI-measured liver fat decreasing by more than 80% from baseline at higher doses 14. While hepatic fat reduction is generally favorable, rapid hepatic changes in a patient with congestive hepatopathy (common in right-sided heart failure) require monitoring. Liver function tests (AST, ALT, bilirubin, albumin) at baseline and every 8 to 12 weeks during treatment are appropriate.

Gastrointestinal Symptoms

Nausea, vomiting, and diarrhea were the most common adverse events in the retatrutide phase 2 trial, occurring in up to 35% of participants at the highest dose 4. For heart failure patients on diuretics and neurohormonal blockers, GI fluid losses can precipitate prerenal azotemia, hyperkalemia from reduced GFR, and dangerous electrolyte imbalances. Slow dose titration (every 4 weeks rather than every 2 weeks) may mitigate this risk.

What the Existing GLP-1 Heart Failure Trials Show (and What They Don't)

The strongest evidence for incretin-based therapy in heart failure comes from two trials of semaglutide.

STEP-HFpEF (N=529) randomized patients with HFpEF, LVEF ≥ 45%, and BMI ≥ 30 to semaglutide 2.4 mg weekly or placebo for 52 weeks. Semaglutide improved the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) by 7.8 points more than placebo and reduced body weight by 13.3% vs. 2.6% 2.

STEP-HFpEF DM (N=616) studied the same regimen in patients with HFpEF, obesity, and type 2 diabetes. KCCQ-CSS improved by 6.4 points vs. placebo, and body weight decreased by 9.8% vs. 3.4% 15.

These results apply to semaglutide only. Extrapolating them to retatrutide assumes that the GLP-1 receptor agonism within retatrutide's triple mechanism produces similar cardiac effects, and that the added GIP and glucagon agonism does not offset or complicate those benefits. Neither assumption has been validated.

Previous trials of GLP-1 agonists in heart failure with reduced ejection fraction (HFrEF) showed no benefit and possible harm. The FIGHT trial (N=300) found that liraglutide did not improve clinical stability in patients with HFrEF and recent hospitalization 16. The 2022 AHA/ACC/HFSA guidelines do not recommend GLP-1 agonists for HFrEF.

Dr. Mikhail Kosiborod, who led the STEP-HFpEF program, emphasized this distinction: "The benefits we observed were specific to patients with HFpEF and obesity. Applying these findings to other heart failure phenotypes, or to other drugs in the incretin class, requires separate evidence" 2.

Trials to Watch

Several ongoing and planned studies will shape the evidence base for retatrutide and heart failure.

The phase 3 TRIUMPH program includes large trials of retatrutide for obesity (TRIUMPH-3, NCT06082856) and type 2 diabetes. These trials include cardiovascular safety endpoints and adjudicated MACE as secondary outcomes, but they exclude patients with NYHA class III-IV heart failure 17.

No dedicated retatrutide heart failure trial has been registered on ClinicalTrials.gov as of May 2026. A cardiovascular outcomes trial (CVOT) for retatrutide has not been publicly announced, though FDA guidance typically requires one for chronic weight-management drugs before or after approval 18.

Until these data emerge, prescribing retatrutide for heart failure is an evidence-free decision. The mechanistic rationale is plausible. Plausibility, however, is the lowest rung of the evidence hierarchy.

Who Should Absolutely Not Receive Retatrutide for Heart Failure

Certain heart failure populations carry prohibitive risk with an unproven triple agonist.

Patients with HFrEF (LVEF <40%) should not receive retatrutide. Existing GLP-1 agonist data in HFrEF (the FIGHT trial) showed no benefit and a trend toward increased heart failure events 16. Adding glucagon-mediated chronotropy to a failing left ventricle could worsen outcomes.

Patients with NYHA class IV symptoms, those hospitalized for acute decompensated heart failure, and those with hemodynamically significant valvular disease are poor candidates. The GI side-effect profile of retatrutide could destabilize volume management in these patients.

Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) have a contraindication to GLP-1 receptor agonists based on preclinical rodent thyroid C-cell tumor findings 19. This warning applies to retatrutide as well.

Patients with a history of pancreatitis should use incretin-based agents with caution. Retatrutide's phase 2 data reported cases of increased lipase levels, though clinical pancreatitis was not observed at a statistically meaningful rate 4.

A Practical Decision Framework for Clinicians

Before prescribing retatrutide off-label for a heart failure patient, the clinician should confirm every item on this checklist:

1. The patient has HFpEF (LVEF ≥ 50%) with obesity (BMI ≥ 30) as a contributing factor.
2. FDA-approved therapies (SGLT2 inhibitors, semaglutide, diuretics, MRAs) have been tried or are contraindicated.
3. The patient understands that retatrutide is not FDA-approved for any indication and that no heart failure efficacy data exist.
4. Informed consent is documented, including discussion of unknown long-term cardiac risks.
5. A monitoring plan covering cardiac biomarkers, heart rate, renal function, electrolytes, and liver enzymes is in place before the first dose.
6. A cardiologist and an endocrinologist (or obesity medicine specialist) are both involved in the patient's care.
7. The starting dose is the lowest available, with titration intervals of at least 4 weeks.
8. Clear stopping rules are defined: sustained tachycardia above 100 bpm, rising NT-proBNP above 25% from baseline, worsening NYHA class, eGFR decline exceeding 25%, or intolerable GI symptoms despite antiemetic therapy.

Skipping any of these steps converts a calculated clinical decision into an unjustifiable gamble.